Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome
Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome
复制标题
抗磷脂酰丝氨酸/凝血酶原抗体（aPS/PT）作为抗磷脂综合征中静脉血栓形成和产科并发症的潜在诊断标志物和风险预测因子
DOI：
10.1515/cclm-2017-0502
复制
发表时间：
2018-04-01
影响因子：
6.8
通讯作者：
Yang, Cheng-De
中科院分区：
文献类型：
--
作者：
Shi, Hui;Zheng, Hui;Yang, Cheng-De
背景：该研究的目的是确定中国抗磷脂酰丝氨酸/凝血凝结蛋白抗体（APS/PT）的患病率和临床关联，中国抗磷脂综合征（APS）患者（APS）患者（APS）患者（APS）和血清酮APS（SNAPS）（SNAPS）的患者（SNAPS）：一百和八年的患者（6）（67）（67）（67）（67）（67）快照，176个疾病控制（79个全身性红斑狼疮[SLE]，29个Sjogren综合征[SS]，30次连直的脊柱炎[AS]，38个类风湿关节炎[RA]）和90个健康供体。 IgG和IgM APS/PT，IgG/IgM/IgA-抗癌蛋白（ACL）和IgG/IgM/IgM/Iga抗-beta（2） - 糖蛋白I（抗-beta（2）GPI）抗体对ELISA.RESA。同种型。 IgG APS/PT的一百三十五（72.6％）为阳性，IGM APS/PT为124/186（66.7％）阳性，两者的阳性为99（53.2％）。大约一半的SNAP患者对IgG和/或IgM APS/PT呈阳性。发现了IgG APS/PT与静脉血栓事件（优势比[OR] = 6.72）和IgG/IgM APS/PT和妊娠损失（OR = 9.44）之间的高度显着关联。在血栓形成表现和胎儿丧失的APS患者中，IgM APS/PT的水平显着差异（P = 0.014）。 IgG/IgM APS/PT与狼疮抗凝剂（LAC）之间的关联非常显着（P <0.001）。当两者均为阳性时，AP的OR为101.6。值得注意的是，91.95％（80/87）的LAC阳性标本对IgG和/或IgM AP/PT呈阳性，当不可用的CONCES concess不可用时，APS/PT表明APS/PT是一个有效的选择。结论：抗PS/PT抗体分析对某些APS患者的诊断范围很高，对APS的患者进行了较高的诊断，AAS的诊断可能会导致AAPS的高度诊断，AAS的诊断可能会受到影响。和产科并发症。
Abstract Background: The aim of the study was to determine the prevalence and clinical associations of antiphosphatidylserine/prothrombin antibodies (aPS/PT) with thrombosis and pregnancy loss in Chinese patients with antiphospholipid syndrome (APS) and seronegative APS (SNAPS). Methods: One hundred and eighty six Chinese patients with APS (67 primary, 119 secondary), 48 with SNAPS, 176 disease controls (79 systemic lupus erythematosus [SLE], 29 Sjogren’s syndrome [SS], 30 ankylosing spondylitis [AS], 38 rheumatoid arthritis [RA]) and 90 healthy donors were examined. IgG and IgM aPS/PT, IgG/IgM/IgA anticardiolipin (aCL) and IgG/IgM/IgA anti-β2-glycoprotein I (anti-β2GPI) antibodies were tested by ELISA. Results: One hundred and sixty (86.0%) of APS patients were positive for at least one aPS/PT isotype. One hundred and thirty five (72.6%) were positive for IgG aPS/PT, 124/186 (66.7%) positive for IgM aPS/PT and 99 (53.2%) positive for both. Approximately half of the SNAPS patients were positive for IgG and/or IgM aPS/PT. Highly significant associations between IgG aPS/PT and venous thrombotic events (odds ratio [OR]=6.72) and IgG/IgM aPS/PT and pregnancy loss (OR=9.44) were found. Levels of IgM aPS/PT were significantly different in APS patients with thrombotic manifestations and those with fetal loss (p=0.014). The association between IgG/IgM aPS/PT and lupus anticoagulant (LAC) was highly significant (p<0.001). When both were positive, the OR for APS was 101.6. Notably, 91.95% (80/87) of LAC-positive specimens were positive for IgG and/or IgM aPS/PT, suggesting aPS/PT is an effective option when LAC testing is not available. Conclusions: Anti-PS/PT antibody assays demonstrated high diagnostic performance for Chinese patients with APS, detected some APS patients negative for criteria markers and may serve as potential risk predictors for venous thrombosis and obstetric complications.